SPRINGFIELD, IL — Raymond Kowalczyk had worked the boiler rooms at a downstate Illinois power plant for 31 years when the shortness of breath started. He ignored it for months. By the time the pulmonologist at Springfield's Memorial Medical Center reviewed his imaging, the diagnosis was unambiguous: malignant pleural mesothelioma, stage III. His daughter, a schoolteacher in Peoria, drove four hours that same night. What she remembers most is not the diagnosis itself, but the question her father asked the oncologist before she even sat down: "Can we still fight this?"
The answer, in 2026, is more complicated and more hopeful than it has ever been. New FDA-approved immunotherapy combinations, tumor-treating field devices, and expanding clinical trial networks have fundamentally changed what's possible for mesothelioma patients. But accessing those options costs money, navigating the system requires expertise, and for families in Illinois, the legal landscape surrounding asbestos exposure claims is one of the most powerful tools available. Understanding how an Illinois mesothelioma lawyer can unlock compensation, and how that compensation connects directly to treatment access, is not just a legal question. It's a survival question.
This article covers what Illinois patients need to know in 2026 about the intersection of legal claims, treatment advances, and financial pathways. It draws on the latest FDA approvals, clinical trial data, and the realities of Illinois asbestos litigation to give patients and families the most complete picture available.
What Has Actually Changed in Mesothelioma Treatment
For most of the early 2000s, mesothelioma treatment meant one thing: pemetrexed and cisplatin. The FDA approved pemetrexed, sold under the brand name Alimta, for mesothelioma in 2004, and for nearly two decades, that platinum-based chemotherapy doublet was the standard of care for patients who couldn't access surgery. It extended median survival. It gave patients months. But it was not a transformation.
That transformation came in October 2020, when the FDA approved nivolumab plus ipilimumab, the combination marketed as Opdivo and Yervoy, for unresectable malignant pleural mesothelioma. According to the FDA's approval announcement, the decision was based on results from the CheckMate 743 trial, a randomized phase III study published in The Lancet. The trial enrolled 605 patients across multiple countries and found that the immunotherapy combination produced a median overall survival of 18.1 months, compared to 14.1 months for standard chemotherapy. More strikingly, patients with non-epithelioid histology, the harder-to-treat subtypes, saw even more dramatic benefit from immunotherapy.
The CheckMate 743 results, published in The Lancet in 2021, represented the first time in 16 years that a new first-line treatment had been approved for mesothelioma. According to the study's findings, 41 percent of patients receiving nivolumab plus ipilimumab were alive at two years, compared to 27 percent in the chemotherapy arm. For a disease where two-year survival had historically been the exception rather than the rule, those numbers matter enormously.
What I hear from patients going through this is that the treatment landscape feels overwhelming at first. The names are unfamiliar, the clinical trial eligibility criteria are confusing, and the financial reality of cutting-edge immunotherapy adds another layer of stress. But the options are real, and they're expanding. Understanding what's available is the first step toward accessing it.
Beyond immunotherapy, a third treatment modality has entered the picture. Tumor Treating Fields, or TTFields, use alternating electrical fields to disrupt cancer cell division. According to a study of the STELLAR trial published in the National Library of Medicine, patients with unresectable pleural mesothelioma who received TTFields in combination with chemotherapy achieved a median overall survival of 18.2 months, with a two-year survival rate of 41 percent. Those numbers are consistent with what the immunotherapy combination achieved, suggesting that multiple pathways now exist toward extended survival. For patients who cannot tolerate immunotherapy or who have progressed on first-line treatment, TTFields represent a legitimate option.
Moffitt Cancer Center's mesothelioma program and MD Anderson's mesothelioma team have both incorporated these newer modalities into their treatment protocols. The SEER database, maintained by the National Cancer Institute, shows that mesothelioma incidence has been slowly declining as occupational asbestos exposure rates dropped in the decades after major regulatory action, but approximately 3,000 Americans are still diagnosed annually, and the disease remains concentrated in industrial states. Illinois is among them.
Why Illinois Has One of the Highest Mesothelioma Burdens in the Nation
To understand why so many Illinois families are navigating mesothelioma simultaneously, you have to understand what Illinois was built on. The state's industrial spine ran from the steel mills of Gary and East Chicago just across the Indiana border, through the refineries and manufacturing corridors of the Chicago metropolitan area, down through the coal country of the southern counties. Shipyards on Lake Michigan, power plants along the Illinois River, construction sites across Cook, DuPage, and Lake Counties, and the rail yards that made Chicago the freight hub of America: all of them used asbestos extensively throughout the mid-twentieth century.
Asbestos was valued for exactly the properties that made it dangerous. It was fire-resistant, flexible, and cheap. Pipe insulation, boiler lagging, gaskets, ceiling tiles, floor tiles, brake linings, and dozens of other industrial materials contained it. The workers who installed, maintained, and removed those materials often had no idea what they were breathing. The companies that made those products frequently did.
The latency period between asbestos exposure and mesothelioma diagnosis typically runs 20 to 50 years. That means the workers who were exposed in Illinois factories, refineries, and construction sites during the 1960s, 1970s, and 1980s are the patients being diagnosed today. Many of them are in their 60s, 70s, and 80s. Many of them worked for companies that are now defunct, reorganized, or operating under different names.
For these patients, the exposure sites directory at Mesothelioma-Lung-Cancer.org can be an essential starting point. Identifying where and when exposure occurred is foundational to any legal claim, and Illinois has dozens of documented high-exposure sites.
How Illinois Asbestos Litigation Works in 2026
Illinois has a well-established legal infrastructure for asbestos claims. Cook County Circuit Court, the state's largest, has processed thousands of asbestos cases over the decades and has specialized procedures for handling them. Madison County, in southwestern Illinois, became one of the most prominent asbestos litigation venues in the country during the 2000s and early 2010s, drawing cases from across the state because of its plaintiff-friendly reputation and experienced judiciary.
An Illinois mesothelioma lawyer typically pursues compensation through one or more of three channels: direct litigation against asbestos manufacturers and distributors, claims against asbestos bankruptcy trust funds, and, where applicable, veterans' benefits claims through the VA.
Direct litigation can result in settlements or jury verdicts. Settlement amounts in mesothelioma cases vary significantly based on the strength of the exposure history, the number of responsible defendants, the patient's age and prognosis, and the jurisdiction. Many mesothelioma cases settle before trial, often for amounts in the hundreds of thousands to millions of dollars.
Asbestos bankruptcy trusts are a parallel system. Because so many asbestos manufacturers filed for bankruptcy protection under the weight of asbestos liability, federal bankruptcy courts required those companies to establish trust funds to compensate future claimants. According to the RAND Corporation's research on asbestos litigation, more than 60 such trusts have been established, holding tens of billions of dollars in aggregate. Patients can file trust claims simultaneously with litigation, and many Illinois mesothelioma cases involve both pathways.
For veterans, a separate pathway exists through the VA. Navy veterans, in particular, face elevated mesothelioma risk because shipboard environments concentrated asbestos in enclosed spaces. The VA benefits eligibility tool can help veterans and their families understand what they may qualify for before consulting an attorney.
The most important step you can take right now, if you or a family member has been diagnosed, is to consult with a mesothelioma-specialized attorney before the statute of limitations closes. In Illinois, the statute of limitations for personal injury asbestos claims is generally two years from the date of diagnosis. For wrongful death claims, it is two years from the date of death. Missing those windows can permanently foreclose compensation that could fund treatment.
The Financial Reality of Advanced Mesothelioma Treatment
This is where legal compensation and medical treatment become inseparable topics.
Nivolumab plus ipilimumab, the FDA-approved first-line immunotherapy combination, carries a list price that can exceed $150,000 per year before insurance adjustments, patient assistance programs, or negotiated rates. TTFields therapy, delivered through the Optune Lua device manufactured by Novocure, has a monthly cost that can exceed $20,000. Even standard chemotherapy with pemetrexed and cisplatin, the regimen approved by the FDA in 2004, involves significant ongoing costs when you factor in anti-nausea medications, supportive care, monitoring, and infusion facility fees.
For patients with strong insurance coverage, some of these costs are manageable. For patients on Medicare, Medicaid, or limited private insurance, the gaps can be enormous. And for patients who are uninsured or underinsured, accessing the most effective treatments can feel impossible without additional financial resources.
Legal compensation changes that calculus. A settlement or trust fund award that delivers $800,000 to $1.2 million, which represents a realistic range for well-documented Illinois mesothelioma cases, can fund years of advanced treatment, cover travel costs to specialized centers, compensate for lost income, and provide financial security for a surviving spouse or dependent children. Many patients and families I've worked with have told me that the legal process, difficult as it is emotionally, gave them options they otherwise wouldn't have had.
The compensation estimator tool provides a starting framework for understanding potential recovery ranges based on exposure history, diagnosis, and other factors.
Choosing the Right Illinois Mesothelioma Lawyer
Not every personal injury attorney is equipped to handle mesothelioma cases effectively. These cases require specialized knowledge: familiarity with industrial exposure sites, understanding of asbestos product identification, access to occupational health experts, and experience navigating both litigation and trust fund claims simultaneously.
What distinguishes a specialized mesothelioma attorney from a general personal injury lawyer is largely a matter of infrastructure. The best mesothelioma law firms maintain databases of exposure sites, employment records, and product identification going back decades. They have relationships with medical experts who can provide testimony on causation. They understand the trust fund system and know which trusts to file claims with based on a client's exposure history. And they work on contingency, meaning they don't collect fees unless they recover compensation.
In Illinois specifically, several factors make attorney selection particularly important. The choice of venue, whether to file in Cook County, Madison County, or another jurisdiction, can significantly affect case outcomes. An experienced Illinois mesothelioma lawyer will analyze the specific facts of a case and make a strategic recommendation about where to file.
When evaluating attorneys, patients and families should ask about the firm's mesothelioma case volume, their experience with Illinois-specific exposure sites, their track record in both litigation and trust fund claims, and how they handle cases for clients who are too ill to travel extensively. Many specialized firms can handle much of the process remotely, which matters enormously for patients whose energy is consumed by treatment.
For families who have already lost a loved one, wrongful death claims follow a similar process but have their own procedural requirements. The patients and families resource section provides guidance on navigating both personal injury and wrongful death claims.
Connecting Legal Compensation to Specialized Treatment Centers
One of the most consequential decisions a mesothelioma patient makes is where to receive treatment. This is not a disease that a community oncologist sees regularly. The best outcomes are consistently associated with high-volume mesothelioma programs at specialized cancer centers.
MD Anderson Cancer Center in Houston has one of the most comprehensive mesothelioma programs in the country, with dedicated surgical, medical oncology, and research teams. According to MD Anderson's program overview, their mesothelioma team offers multimodal treatment including surgery, chemotherapy, immunotherapy, and access to clinical trials. Moffitt Cancer Center in Tampa similarly maintains a specialized mesothelioma program with research integration.
For Illinois patients, the University of Chicago Medicine and Northwestern Memorial Hospital both have thoracic oncology programs with mesothelioma experience. Rush University Medical Center in Chicago has also treated mesothelioma patients with access to newer treatment protocols.
The practical challenge is that traveling to a specialized center, whether in Chicago or out of state, requires financial resources. Hotel costs, transportation, time away from work for a caregiver, and the logistical burden of managing treatment at a distance from home all add up. Legal compensation can fund that access. Many patients who receive settlements use a portion of the funds specifically to access specialized care they couldn't otherwise afford.
Clinical trials represent another layer of access. Open trials recruiting mesothelioma patients represent opportunities to access treatments not yet commercially available, often at no cost to the patient for the investigational therapy itself. The most important step you can take right now, if you're interested in clinical trials, is to ask your oncologist about eligibility and to have a specialized mesothelioma attorney help you understand how trial participation interacts with your legal claims.
Understanding the Treatment Pipeline: What's Coming Next
The pace of mesothelioma research has accelerated meaningfully since the CheckMate 743 results were published. Research published in Nature's mesothelioma subject area and in the interdisciplinary journal Cancer has explored several promising directions that Illinois patients should know about.
CAR-T cell therapy, which engineers a patient's own immune cells to recognize and attack cancer, is being investigated for mesothelioma in early-phase trials. Mesothelin, a protein expressed at high levels on mesothelioma cells, is an attractive target because it's relatively specific to the tumor. Early results from mesothelin-targeted approaches have been encouraging, though the therapy remains investigational.
Anti-angiogenic agents, which starve tumors by blocking blood vessel formation, are being combined with immunotherapy in trials exploring whether the combination can improve on what nivolumab plus ipilimumab achieves alone. Bevacizumab, which targets VEGF signaling, has shown activity in mesothelioma in some studies and is being evaluated in combination regimens.
For peritoneal mesothelioma, a distinct form of the disease affecting the abdominal lining rather than the chest cavity, cytoreductive surgery combined with heated intraperitoneal chemotherapy, known as HIPEC, has produced the most dramatic survival outcomes of any mesothelioma treatment. Selected patients with peritoneal mesothelioma who undergo complete cytoreduction and HIPEC have achieved median survivals exceeding five years in some series. The challenge is that this procedure is highly specialized and available at only a small number of centers nationally.
For Illinois patients with peritoneal mesothelioma, identifying a surgeon experienced with HIPEC is critical. The University of Chicago and Northwestern both have surgeons with peritoneal surface malignancy experience, and several specialized programs exist in the Midwest.
Understanding the full landscape of treatment options, from standard chemotherapy through immunotherapy, TTFields, HIPEC, and emerging clinical trials, requires the kind of comprehensive guidance that a mesothelioma specialist can provide. The diagnosis and treatment resource hub offers a structured overview of the treatment decision process.
The Emotional Architecture of Simultaneous Legal and Medical Battles
There's a moment that many families describe similarly. The oncologist has just explained the treatment plan. The patient is absorbing the information, asking questions, trying to hold everything together. And then, often within days, a family member or a social worker raises the question of legal options. It can feel jarring, even inappropriate. Like the family is being asked to think about money when they should be thinking about survival.
But the reality is that these two processes are deeply intertwined, and pursuing legal compensation doesn't distract from treatment. For most patients, it enables it.
What I hear from patients going through this is that the legal process, handled by a competent specialized attorney, requires surprisingly little of the patient's energy once it's initiated. The attorney manages the discovery, the document gathering, the expert coordination, and the negotiation. The patient's primary job is to provide their employment history and exposure information and to focus on treatment.
The emotional weight is real, though. Depositions, even when conducted remotely or in a patient's home, require revisiting decades of work history and exposure. Wrongful death claims require a surviving family to engage with legal proceedings while still grieving. Many patients and families I've worked with have found it helpful to designate a family member as the primary point of contact with the legal team, so the patient can focus on treatment while the family manages the legal logistics.
Support resources matter here. The answers section provides responses to common questions patients and families have during the legal and treatment process. The patients and families hub offers broader guidance on navigating the emotional and practical dimensions of a mesothelioma diagnosis.
Immunotherapy Access: The Insurance and Coverage Challenge
Even for patients who have received a mesothelioma diagnosis and whose oncologist recommends nivolumab plus ipilimumab as first-line therapy, getting that treatment covered is not automatic.
Insurers sometimes require prior authorization for immunotherapy combinations. They may require documentation that the patient meets specific clinical criteria, that alternative treatments have been considered, or that the treatment is being administered at a facility that meets certain standards. For elderly patients on Medicare, coverage pathways exist but require navigation.
The FDA's approval of nivolumab plus ipilimumab for unresectable malignant pleural mesothelioma established medical necessity for appropriate patients. That approval is a critical tool in insurance appeals. When an insurer denies coverage for an FDA-approved first-line treatment, the denial can be appealed, and the FDA approval provides the foundation for that appeal.
Pharmaceutical manufacturer patient assistance programs can also bridge gaps. Bristol Myers Squibb, which markets nivolumab and ipilimumab, has patient assistance programs for patients who meet income criteria. These programs can provide the drugs at no cost or reduced cost for patients who don't have adequate insurance coverage.
Legal compensation, again, enters this picture directly. Patients who have received settlements or trust fund distributions have the financial resources to self-pay for treatment periods while insurance appeals are pending, to access out-of-network specialists, and to cover the supportive care costs that insurance often doesn't fully reimburse.
For patients exploring immunotherapy options in more detail, the encyclopedia entry provides a comprehensive overview of how these treatments work and what to expect.
The Role of Second Opinions in Treatment Planning
One of the most consistent pieces of advice that mesothelioma specialists offer is to seek a second opinion before finalizing a treatment plan. This is not a reflection on the competence of the initial treating oncologist. It reflects the complexity of mesothelioma and the degree to which treatment decisions, particularly around surgery eligibility, can vary between institutions.
The question of whether a patient is a candidate for surgery, either extrapleural pneumonectomy or the less extensive pleurectomy and decortication, is one of the most consequential decisions in mesothelioma management. Surgical eligibility depends on tumor extent, histology, the patient's overall fitness, and the surgical team's experience. A patient told they are not a surgical candidate at one institution may receive a different assessment at a high-volume mesothelioma center.
Similarly, the question of whether to pursue immunotherapy, chemotherapy, TTFields, or a combination approach benefits from specialist input. MD Anderson and Moffitt both offer second opinion consultations, and many can be conducted remotely through telemedicine for patients who cannot travel.
The cost of a second opinion, including travel if necessary, is often covered by insurance. If not, it's a cost that mesothelioma legal compensation can fund. Many patients and families I've worked with have described a second opinion as the decision that opened a treatment pathway they didn't know existed.
Illinois-Specific Legal Considerations: Venue, Timing, and Asbestos Trust Claims
Illinois has several features that make it a distinctive jurisdiction for mesothelioma litigation. Understanding them can help patients and families have more informed conversations with their legal teams.
Cook County Circuit Court handles the largest volume of asbestos cases in Illinois and has a sophisticated asbestos docket. Cases in Cook County can move relatively efficiently through the system because judges and court staff are familiar with the procedural requirements. Madison County, historically one of the most plaintiff-favorable asbestos venues in the country, has seen some changes in its litigation environment over the past decade as tort reform efforts affected filing patterns, but it remains an active venue for mesothelioma cases with appropriate connections to the county.
Illinois law allows mesothelioma patients to pursue what are called "discovery rule" claims, meaning the statute of limitations clock begins running from the date the patient knew or reasonably should have known they had an asbestos-related disease. This is critically important for mesothelioma, where exposure may have occurred decades before diagnosis. The two-year window runs from diagnosis, not from the last date of exposure.
For wrongful death claims in Illinois, the two-year clock runs from the date of death. Families who lose a loved one to mesothelioma before a personal injury claim is resolved can convert or supplement the claim as a wrongful death action. An experienced Illinois mesothelioma lawyer will manage this transition.
Asbestos trust fund claims in Illinois follow federal procedures established by the individual trusts, not state law. Many trusts accept claims based on documented exposure and a confirmed mesothelioma diagnosis, without requiring litigation. The amounts available from trusts vary widely, from tens of thousands of dollars from smaller trusts to hundreds of thousands from larger ones. A specialized attorney will know which trusts are relevant to a given client's exposure history and will file claims simultaneously with or independently of litigation.
For patients whose asbestos exposure occurred at military facilities or during military service, the intersection of VA benefits and legal claims requires careful navigation. VA disability compensation and legal settlements can coexist, but the specifics depend on the type of VA benefit involved. The VA benefits eligibility tool is a useful starting point, and a specialized attorney can advise on how to maximize recovery across both channels.
What the Data Shows: Survival Trends and Treatment Outcomes
The SEER database maintained by the National Cancer Institute provides the most comprehensive population-level data on mesothelioma outcomes in the United States. According to SEER statistics, the five-year relative survival rate for mesothelioma overall remains below 12 percent. But that aggregate number obscures significant variation based on histology, stage at diagnosis, treatment received, and access to specialized care.
Patients with epithelioid histology, the most common subtype, have better outcomes than those with sarcomatoid or biphasic disease. Patients diagnosed at earlier stages have better outcomes than those with advanced disease, though mesothelioma is frequently diagnosed late because symptoms are nonspecific and the disease mimics more common conditions. And patients treated at high-volume specialized centers consistently show better outcomes than those treated in general oncology settings, a pattern documented across multiple cancer types and particularly pronounced for rare cancers like mesothelioma.
The CheckMate 743 trial data, published in The Lancet, provides the most relevant contemporary benchmark for first-line treatment outcomes. The 18.1-month median overall survival in the immunotherapy arm, compared to 14.1 months in the chemotherapy arm, represents a meaningful improvement. The two-year survival rate of 41 percent in the immunotherapy arm is particularly significant for patients and families trying to understand what treatment might make possible.
The STELLAR trial data on TTFields, published in the National Library of Medicine, showed comparable outcomes with a different mechanism. The convergence of multiple treatment approaches around the 18-month median survival mark suggests that this may represent something close to the current ceiling for systemic therapy in unresectable disease, and that breaking through that ceiling will require either better patient selection, combination approaches, or the next generation of targeted therapies.
For patients with resectable disease who undergo surgery at specialized centers, outcomes can be substantially better. The most favorable surgical candidates, typically those with epithelioid histology, limited nodal involvement, and good performance status, can achieve median survivals exceeding 24 months with multimodal therapy including surgery, chemotherapy, and radiation.
Building a Care Team: Who Should Be on It
A mesothelioma diagnosis requires a multidisciplinary care team, and building that team intentionally produces better outcomes than defaulting to whoever is available.
The core team should include a thoracic oncologist with mesothelioma experience, a thoracic surgeon who can evaluate surgical candidacy even if surgery is ultimately not pursued, and a pulmonologist if respiratory symptoms require management. A palliative care specialist should be integrated from the beginning, not reserved for end-of-life care. Palliative care improves quality of life and can actually extend survival by managing symptoms that would otherwise interrupt or delay treatment.
Beyond the medical team, the extended care team should include a patient navigator or social worker familiar with cancer financial assistance programs, a mesothelioma-specialized attorney, and ideally a connection to a mesothelioma patient advocacy organization. The Mesothelioma Applied Research Foundation and the Asbestos Disease Awareness Organization both provide patient support resources and connections to the research community.
For patients dealing with the intersection of lung cancer and asbestos-related conditions, understanding the distinctions between mesothelioma and asbestos-related lung cancer matters for both treatment planning and legal claims. The two diseases have different legal standards for causation and different treatment approaches.
The most important step you can take right now in building your care team is to request a referral to a thoracic oncologist with specific mesothelioma experience, not just general lung cancer experience. The treatment protocols are distinct, the clinical trial landscape is distinct, and the expertise required is distinct.
The Long Game: What Patients and Families Should Plan For
Mesothelioma treatment in 2026 is not a sprint. With immunotherapy extending survival for many patients, and with some patients on TTFields or in clinical trials achieving outcomes well beyond historical norms, the disease has become, for some patients, a chronic condition to be managed over years rather than months.
That shift has practical implications. Patients need to plan for extended treatment periods, ongoing monitoring, and the possibility of second-line therapy after first-line treatment stops working. They need to think about caregiver support structures that can sustain over a longer period. They need to consider the financial planning dimensions of a disease that may require expensive treatment for two, three, or more years.
Legal compensation, when it arrives, needs to be managed thoughtfully. Many mesothelioma families work with financial advisors to structure settlement funds in ways that provide ongoing income for treatment costs while also protecting assets for a surviving spouse or dependents. An experienced mesothelioma attorney will often have relationships with financial planners who specialize in this context.
The emotional long game is equally important. Patients living with mesothelioma for extended periods on treatment face a particular kind of psychological challenge: the ongoing uncertainty of a disease that can progress, the side effects of immunotherapy or other treatments that affect daily life, and the need to maintain hope while also planning realistically. Mental health support, whether through individual therapy, support groups, or both, is not optional. It's part of treatment.
Many patients and families I've worked with have found that connecting with other mesothelioma patients, through advocacy organizations, online communities, or hospital-based support groups, provides a form of support that clinical care alone cannot offer. The knowledge that others are navigating the same terrain, that survival is possible, that the fight is worth having, is itself therapeutic.
Raymond Kowalczyk, the Springfield patient whose story opened this article, ultimately enrolled in a clinical trial at a Chicago research center after receiving a settlement that funded his travel and lodging. His daughter took a leave of absence from teaching to accompany him during the first treatment cycle. He's still in the trial. The question he asked that first night, "Can we still fight this?" turned out to have an answer worth hearing.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.
